Data Mining Case Struck Down by Supreme Court; IMS Prepares for Future Battles
This article was originally published in RPM Report
Executive Summary
When the Supreme Court threw out a Vermont law that prevented pharmaceutical companies from using physician prescribing data for marketing purposes, the unexpectedly broad opinion was cheered by Big Pharma and data miners alike. But IMS Health is already gearing up for the next data mining battle. And this time, the company says, the fight will be about protecting patient privacy.
You may also be interested in...
Off-Label Sales in Jeopardy: Rx Industry Fights for Clarity
Off-label use of prescription drugs is worth billions of dollars to manufacturers, but no one likes to talk about it. Defensiveness is understandable, with scores of companies under investigations for allegedly promoting those uses illegally. The truth is that no one is very happy about the current state of off-label medication use, but calls for change are contradictory and tough to resolve.
Flying Blind: Learning to Live Without Physician Prescribing Data
Physicians aren't happy about the prescribing information companies use to help develop sales and marketing activities, and they're doing something about it. Policies adopted by medical professionals--and legislation moving at the state level--threaten to cut off marketers' access to information about who prescribes their products. Pharma companies better prepare to adapt to new ways of tracking sales.
Loose Lips Sink Ships
In the debate over prescribing data, just a causal conversation between a sales rep and a physician can inspire efforts to ban the practice. The following anecdotes underscore the importance--and the difficulty-in maintaining control over sales forces.